4DMedical Expands U.S. Reach Through SimonMed Imaging Partnership
4DMedical Limited (ASX: 4DX) has secured a commercial agreement with SimonMed Imaging, one of the largest outpatient imaging providers in the United States, marking a significant step in the expansion of its respiratory imaging technology. Under the three-year agreement, SimonMed will deploy 4DMedical’s CT™ and LDAf™ solutions across its extensive imaging network, supporting enhanced cardiopulmonary assessment and clinical decision-making.
The partnership provides immediate commercial deployment without a trial phase, highlighting growing confidence in the company’s technology and its ability to deliver actionable insights from standard CT scans. The agreement also creates an opportunity to strengthen reimbursement pathways through the collection of insurance and claims data across SimonMed’s network.
Management believes the contract supports the company’s strategy of increasing adoption of its software-as-a-service imaging solutions while expanding its presence in the U.S. healthcare market. The collaboration is expected to enhance long-term growth prospects as demand for advanced lung imaging technologies continues to rise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
4DMedical Expands U.S. Reach Through SimonMed Imaging Partnership
4DMedical Limited (ASX: 4DX) has secured a commercial agreement with SimonMed Imaging, one of the largest outpatient imaging providers in the United States, marking a significant step in the expansion of its respiratory imaging technology. Under the three-year agreement, SimonMed will deploy 4DMedical’s CT™ and LDAf™ solutions across its extensive imaging network, supporting enhanced cardiopulmonary assessment and clinical decision-making.
The partnership provides immediate commercial deployment without a trial phase, highlighting growing confidence in the company’s technology and its ability to deliver actionable insights from standard CT scans. The agreement also creates an opportunity to strengthen reimbursement pathways through the collection of insurance and claims data across SimonMed’s network.
Management believes the contract supports the company’s strategy of increasing adoption of its software-as-a-service imaging solutions while expanding its presence in the U.S. healthcare market. The collaboration is expected to enhance long-term growth prospects as demand for advanced lung imaging technologies continues to rise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au